Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Exosomes & Liquid Biopsies Europe 2018

Klaus Pantel's Biography



Klaus Pantel, Director, University Of Hamburg

Prof. Klaus Pantel graduated in 1986 from Cologne University in Germany and completed his thesis on mathematical modelling of hematopoiesis in 1987. After his postdoctoral period in the USA on hematopoietic stem cell regulation (Wayne State University, Detroit), he performed research on cancer micrometastasis at the Institute of Immunology, University of Munich for 10 years. Currently, Prof Pantel is Chairman of the Institute of Tumour Biology at the University Medical Center Hamburg-Eppendorf. The institute is part of the University Cancer Center Hamburg (UCCH). The pioneer work of Prof Pantel in the field of cancer micrometastasis, circulating tumor cells and circulating nucleic acids (ctDNA, microRNAs) is reflected by more than 300 publications in excellent high ranking biomedical and scientific journals (incl. NEJM, Lancet, Nature Journals, Cancer Cell, PNAS, JCO, JNCI, Cancer Res.) and has been awarded recently (AACR Outstanding Investigator Award 2010, German Cancer Award 2010, ERC Advanced Investigator Grant 2011). Moreover, Prof Pantel was co-ordinator of the FP6 EU STREP “DISMAL” (Disseminated Malignancies, www.dismal-project.eu), coordinates now the European TRANSCAN group “CTC-SCAN” and the EU IMI Network Project “CANCER-ID” (www.cancer-id.eu) and serves on the Editorial Boards of international cancer journals (e.g., Clin. Cancer Res., Breast Cancer Res., Cancer Res.).

Klaus Pantel Image

Liquid Biopsy: The New Diagnostic Concept in Oncology

Wednesday, 24 October 2018 at 11:15

Add to Calendar ▼2018-10-24 11:15:002018-10-24 12:15:00Europe/LondonLiquid Biopsy: The New Diagnostic Concept in OncologyExosomes and Liquid Biopsies Europe 2018 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com

The analysis of circulating tumor cells (CTCs) in blood may provide clinically relevant information as “liquid biopsy” (Alix-Panabieres & Pantel, Nature Rev Cancer 2014) and provide new insights into tumor biology (Uhr & Pantel, PNAS, 2011, Lu et al., Cancer Cell, 2011; LeBleu et al., Nat. Cell Biol., 2014; Werner et al., Cancer Discovery, 2015). Besides CTCs the molecular analysis of ctDNA provides important complementary information as “liquid biopsy” (Pantel & Alix-Panabieres, Cancer Res., 2013; Pantel et al., Nature Med. 2013; Heitzer et al., Genome Med. 2013; Schwarzenbach et al., Nature Rev. Clin. Oncol., 2014, Joosse & Pantel, Cancer Cell 2015; Bardelli & Pantel, Cancer Cell 2017). Moreover, circulating microRNAs, extracellular vesicles and tumor-educated platelets are also interesting new members of the “Liquid Biopsy family” with potential clinical relevance in the future. In particular exosomes have gained great interest because they act as biomarkers with important functional properties for tumor progression. E.g., the integrin composition of exosomes can determine the organ site of metastases (Hoshino, Pantel, Lyden et al., Nature, 2015) and microRNAs in exosomes can impact the biology of the recipient cells (Anfossi, Bababayan, Pantel, Calin, Nature. Rev. Clin. Oncol. 2018). Detection of these miRNAs can contribute to early detection of cancer (Meng et al., Oncotarget, 2016). Liquid biopsy analyses with validated platforms provides reliable information on prognosis and may serve to identify therapeutic targets or mechanisms of resistance on metastatic cells. Metastatic cells might have unique characteristics that can differ from the bulk of cancer cells in the primary tumor currently used for stratification of patients to systemic therapy. Moreover, monitoring of blood samples before, during and after systemic therapy (e.g., chemotherapy, hormonal therapy, antibody therapy) might provide unique information for the future clinical management of the individual cancer patient and might serve as surrogate marker for response to therapy. In conclusion, liquid biopsies can be used to improve the management of individual cancer patients and contribute to the vision of personalized medicine (Alix-Panabieres & Pantel, Cancer Discovery, 2016; Bardelli & Pantel, Cancer Cell 2017). Validation of liquid biopsy assays is essential and is currently being performed by the EU/IMI consortium CANCER-ID (www.cancer-id.eu).


Add to Calendar ▼2018-10-24 00:00:002018-10-26 00:00:00Europe/LondonExosomes and Liquid Biopsies Europe 2018Exosomes and Liquid Biopsies Europe 2018 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com